Published in Cardiovascular Business Week, October 26th, 2004
SPIRIT FIRST is a prospective, randomized, single-blind trial evaluating Guidant's MULTI-LINK VISION-based everolimus eluting coronary stent system utilizing a durable polymer versus an uncoated MULTI-LINK VISION Coronary Stent System control in de novo (previously untreated) lesions.
Angiographic in-stent late loss at 6 months, the study's primary endpoint, was 0.10 mm for the MULTI-LINK VISION-based everolimus eluting stent system and 0.84 mm for the control arm. The in-stent angiographic binary restenosis rate for the everolimus...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.